About: Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence
Creator	Kuster, Gabriela Osswald, Stefan
Source	Medline; PMC
abstract	covid:84b256bd3d1e04fd93efbba3f58f32d9e284e0da#abstract
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1093/eurheartj/ehaa335
bibo:pmid	32324223
has license	no-cc
sha1sum (hex)	84b256bd3d1e04fd93efbba3f58f32d9e284e0da
schema:url	https://doi.org/10.1093/eurheartj/ehaa335
resource representing a document's title	Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence
has PubMed Central identifier	PMC7188138
has PubMed identifier	32324223
schema:publication	Eur Heart J
resource representing a document's body	covid:84b256bd3d1e04fd93efbba3f58f32d9e284e0da#body_text
is schema:about of	named entity 'ARBs' named entity 'COVID' named entity 'COVID-19' named entity 'ARDS' named entity 'COVID-19' named entity 'hypertensive' named entity 'drug class' named entity 'calcium channel blockers' named entity 'metaanalysis' named entity 'antihypertensive therapy' named entity 'antihypertensive' named entity 'China' named entity 'ACEIs' named entity 'calcium channel blockers' named entity 'ARBs' named entity 'lung' named entity 'angiotensin-converting enzyme inhibitors' named entity 'ACEIs' named entity 'COVID-19 disease' named entity 'China' named entity 'amlodipine' named entity 'pulmonary disease' named entity 'Ang1' named entity 'calcium channel blockers' named entity 'hypertensive' named entity 'ARBs' named entity 'ARBs' named entity 'ACEIs' named entity 'ACEIs' named entity 'ACEI' named entity 'pneumonia' named entity 'viral load' named entity 'ACEIs' named entity 'Italy' named entity 'ACEI' named entity 'ACEIs' named entity 'COVID' named entity 'antihypertensive drugs' named entity 'angiotensin receptor blockers' named entity 'ARBs' named entity 'COVID' named entity 'angiotensin II' named entity 'COVID' named entity 'ARBs' named entity 'antihypertensive medication' named entity 'antihypertensive therapy' named entity 'COVID-19' named entity 'WAIT' named entity 'therapy' named entity 'COVID-19' named entity 'wait' named entity 'evidence' named entity 'Switching' named entity 'antihypertensive' named entity 'EVIDENCE' named entity 'WHY' named entity 'COVID-19' named entity 'SWITCHING' named entity 'TIMES' named entity 'ANTIHYPERTENSIVE THERAPY'
is part of of	Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence covid:84b256bd3d1e04fd93efbba3f58f32d9e284e0da#body_text covid:84b256bd3d1e04fd93efbba3f58f32d9e284e0da#abstract

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software